Doximity, Inc. (DOCS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Jun 12, 2026
Current Price
$20.04
Price Target
$29.47
Target Range
$18.00 — $59.00
Analyst Rating
Hold
Forward P/E14.0x
Trailing P/E20.4x
Forward PEG0.27
Implied Growth+42.5%
Median Target$26.00
Analyst Spread139.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$18
-10.2%
Consensus
$29
+47.1%
Bull Case
$59
+194.4%
Valuation Model TargetsConfidence: 64/100
Bear$22
Base$31
Bull$62
DOCS Price Target Analysis
Updated June 13, 2026As of June 13, 2026, Doximity, Inc. (DOCS) has a Wall Street consensus price target of $29.47, based on estimates from 23 covering analysts. With the stock currently trading at $20.04, this represents a potential upside of +47.1%. The company has a market capitalization of $3.75B.
Analyst price targets range from a low of $18.00 to a high of $59.00, representing a 139% spread in expectations. The median target of $26.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 10 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, DOCS trades at a trailing P/E of 20.4x and forward P/E of 14.0x. The forward PEG ratio of 0.27 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +42.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $31.45, with bear and bull scenarios of $22.01 and $61.71 respectively. Model confidence stands at 64/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+24.7%
Avg Forward P/E31.2x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HIMSHims & Hers Health, Inc. | $5.9B | $26.82 | $27.00 | +0.7% | Hold | — | 20 |
 WELLWelltower Inc. | $150.1B | $214.23 | $239.11 | +11.6% | Buy | 74.0x | 34 |
 NVCRNovoCure Limited | $2.0B | $17.78 | $33.50 | +88.4% | Buy | — | 15 |
 VEEVVeeva Systems Inc. | $25.9B | $159.54 | $235.38 | +47.5% | Buy | 17.6x | 43 |
 INVAInnoviva, Inc. | $1.7B | $22.74 | $40.00 | +75.9% | Buy | 6.4x | 10 |
 PGNYProgyny, Inc. | $2.1B | $26.63 | $30.33 | +13.9% | Buy | 20.8x | 20 |
 TDOCTeladoc Health, Inc. | $1.3B | $7.34 | $7.40 | +0.8% | Hold | — | 42 |
 AMWLAmerican Well Corporation | $152M | $9.11 | $6.33 | -30.5% | Hold | — | 15 |
 HCATHealth Catalyst, Inc. | $137M | $1.85 | $2.25 | +21.6% | Buy | 47.7x | 22 |
 PINCPremier, Inc. | $2.3B | $28.26 | $33.15 | +17.3% | Hold | 20.8x | 31 |
Upside Potential Comparison
NVCRINVAVEEVHCATPINCPGNYWELLTDOCWhat if you invested $1,000 in DOCS 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in DOCS be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs DOCS Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationDOCS vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowDOCS — Frequently Asked Questions
Quick answers to the most common questions about buying DOCS stock.
What is the DOCS stock price target for 2026?
The consensus Wall Street price target for DOCS is $29.47, representing 47.1% upside from the current price of $20.04. With 23 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is DOCS a buy, sell, or hold?
DOCS has a consensus rating of "Hold" based on 23 Wall Street analysts. The rating breakdown is mixed, with 13 Hold ratings making up the largest segment. The consensus 12-month price target of $29.47 implies 47.1% upside from current levels.
Is DOCS stock overvalued or undervalued?
With a forward P/E of 13.9856x, DOCS trades at a relatively low valuation. The consensus target of $29.47 implies 47.1% appreciation, suggesting meaningful undervaluation.
How high can DOCS stock go?
The most bullish Wall Street analyst has a price target of $59 for DOCS, while the most conservative target is $18. The consensus of $29.47 represents the median expectation. Our quantitative valuation model projects a bull case target of $62 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover DOCS stock?
DOCS is well covered by analysts, with 23 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 9 have Buy ratings, 13 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the DOCS stock forecast?
The 12-month DOCS stock forecast based on 23 Wall Street analysts shows a consensus price target of $29.47, with estimates ranging from $18 (bear case) to $59 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $31, with bear/bull scenarios of $22/$62.
What is DOCS's fair value based on fundamentals?
Our quantitative valuation model calculates DOCS's fair value at $31 (base case), with a bear case of $22 and bull case of $62. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 64/100.
What is DOCS's forward P/E ratio?
DOCS trades at a forward P/E ratio of 14.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 20.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy DOCS stock?
Wall Street analysts are very optimistic on DOCS, with a "Hold" consensus rating and $29.47 price target (47.1% upside). 10 of 23 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do DOCS price targets vary so much?
DOCS analyst price targets range from $18 to $59, a 139% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $29.47 consensus represents the middle ground. Our model's $22-$62 range provides an independent fundamental perspective.